COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,626 Articles (22,913 medRxiv, 8,713 bioRxiv)

Most recent first Previous |  Page 334: Articles 3331-3340  | Next

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial
Thiem, V. D., Anh, D. D., Ha, V. H., Van Thom, N., Thang, T. C., Mateus, J., Carreno Quiroz, J. M., Raghunandan, R., Huong, N. M., Mercer, L., Flores, J., Escarrega, E. A., Raskin, A., Thai, D. H., Be, L. V., Sette, A., Innis, B. L., Krammer, F., Weiskopf, D.
10.1101/2023.11.30.23299208 — Posted: 2023-12-01
Fitness models provide accurate short-term forecasts of SARS-CoV-2 variant frequency
Abousamra, E., Figgins, M. D., Bedford, T.
10.1101/2023.11.30.23299240 — Posted: 2023-12-01
Caveolin scaffolding domain (CSD) peptide LTI-2355 modulates the phagocytic and synthetic activity of lung derived myeloid cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-acute sequelae of COVID-fibrosis (PASC-F)
Creyns, B., MacKenzie, B., Sa, Y., Coelho, A. L., Christensen, D., Parimon, T., Windsor, B., Hogaboam, C. M.
10.1101/2023.12.01.569608 — Posted: 2023-12-01
Gut Microbiome Dynamics and Predictive Value in Hospitalized COVID-19 Patients: A Comparative Analysis of Shallow and Deep Shotgun Sequencing
Kopera, K., Gromowski, T., Wydmanski, W., Skonieczna-Zydecka, K., Muszynska, A., Zielinska, K., Wierzbicka-Wos, A., Kaczmarczyk, M., Kadaj-Lipka, R., Cembrowska-Lech, D., Januszkiewicz, K., Koftis, K., Witkiewicz, W., Nalewajska, M., Feret, W., Marlicz, W., Labaj, P. P., Rydzewska, G., Kosciolek, T.
10.1101/2023.11.29.568526 — Posted: 2023-11-30
SARS-CoV-2 NSP13 suppresses the Hippo pathway downstream effector YAP
Meng, F., Kim, J. H., Tsai, C.-R., Wang, J., Shi, Y., Deshmukh, V., Li, X., Steimle, J., Xie, B., Li, R. G., Martin, J.
10.1101/2023.11.30.569413 — Posted: 2023-11-30
Antiviral humoral immunity against SARS-CoV-2 Omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals
Kosugi, Y., Kaku, Y., Hinay, A. A., Guo, Z., Uriu, K., Kihara, M., Saito, F., Uwamino, Y., Kuramochi, J., Shirakawa, K., Takaori-Kondo, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Sato, K.
10.1101/2023.11.29.569330 — Posted: 2023-11-30
Persistent immune imprinting after XBB.1.5 COVID vaccination in humans
Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J., Sprouse, K., Logue, J., Clarke, E., Franko, N., Chu, H., Veesler, D.
10.1101/2023.11.28.569129 — Posted: 2023-11-30
Mechanistic insights into ligand dissociation from the SARS-CoV-2 spike glycoprotein
Hasse, T. A., Mantei, E., Shahoei, R., Pawnikar, S., Wang, J., Miao, Y., Huang, Y.-m. M.
10.1101/2023.11.29.569184 — Posted: 2023-11-30
COVID-19 infection wave mortality from surveillance data in the Philippines using machine learning
Migrino, J. R., Batangan, A. R. U., Abello, R. M. R.
10.1101/2023.11.28.23299037 — Posted: 2023-11-30
Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) Extension study
Wertenauer, C., Dressel, A., Wieland, E., Wertenauer, H.-J., Braitmaier, H., Straub, A., Luetzner, N., Maerz, W.
10.1101/2023.11.29.23299183 — Posted: 2023-11-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).